Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

Figure 1 Crohn’s disease (A) and ulcerative colitis (B) indices after 3, 6, 9, and 12 mo of CT-P13 treatment. Error bars indicate SD. ^bP < 0.001 vs baseline conditions.

Figure 2 General inflammatory blood biomarkers. C-reactive protein levels, erythrocyte sedimentation rate, and fecal calprotectin levels were measured at baseline and after 3, 6, 9, and 12 mo of CT-P13 treatment in patients with Crohn’s disease (A) and ulcerative colitis (B). Error bars indicate SD. ^aP < 0.05 vs baseline conditions; ^bP < 0.01 vs baseline conditions; ^cP < 0.001 vs baseline conditions.